Is Bright Minds Biosciences Inc. (DRUG.CN) a Buy, Sell, or Hold?
CNQ : DRUG.CN
Bright Minds Biosciences Inc.
$107.43 CAD
-$2.53 (-2.3%)
- Volume
- 500
- Average Volume
- 967
- Market Capitalization
- $833.82M
- P/E Ratio
- -31.69
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $170.00
- Year Low
- $37.47
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $81.48
Company Overview
CNQ
Ian McDonald
Biotechnology
Healthcare
DRUG.CN
26
US
CAD
Liquidity Metrics
0.00
81.48
81.48
80.76
0.00
Sales & Valuation
-$
0.00
3.35
-41.57
-2.09
Profitability
-$1.78
-$12.23M
0.00%
0.00%
-20.73%
-8.83%
P/E Metrics
-31.69
0.29
0.29
Analyst Price Target & Rating
2/5
4 Analysts
%
Financial Health Scores
134.61
1/9
$307.45M
$311.34M
$3.82M
-$31.39M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Emer Leahy | Consultant |
| Ian McDonald | Co-Founder, Chief Executive Officer, President & Director |
| Ryan E. S. K. Cheung | CFO & Corporate Secretary |
| Stephen D. Collins | Chief Medical Officer |
| Alex Vasilkevich | Chief Operating Officer & Senior Scientific Officer |
| Jan Torleif Pedersen | Chief Science Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Bright Minds Biosciences Inc. (CNQ:DRUG.CN) Stock
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the ... Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Frequently Asked Questions
-
What is the current Bright Minds Biosciences Inc. (DRUG.CN) stock price?
-
Bright Minds Biosciences Inc.(CNQ:DRUG.CN) stock price is $107.43 in the last trading session. During the trading session, DRUG.CN stock reached the peak price of $170 while $37.47 was the lowest point it dropped to. The percentage change in DRUG.CN stock occurred in the recent session was --2.3% while the dollar amount for the price change in DRUG.CN stock was -$2.53.
-
DRUG.CN's industry and sector of operation?
-
The CNQ listed DRUG.CN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DRUG.CN?
-
Emer Leahy | Consultant
Ian McDonald | Co-Founder, Chief Executive Officer, President & Director
Ryan E. S. K. Cheung | CFO & Corporate Secretary
Stephen D. Collins | Chief Medical Officer
Alex Vasilkevich | Chief Operating Officer & Senior Scientific Officer -
How many employees does DRUG.CN have?
-
Number of DRUG.CN employees currently stands at 26. DRUG.CN operates from 19 Vestry Street, New York, NY 10013, US.
-
Link for DRUG.CN official website?
-
Official Website of DRUG.CN is: https://www.brightmindsbio.com
-
How do I contact DRUG.CN?
-
DRUG.CN could be contacted at phone #647 407 2515 and can also be accessed through its website. DRUG.CN operates from 19 Vestry Street, New York, NY 10013, US.
-
How many shares of DRUG.CN are traded daily?
-
The average number of DRUG.CN shares traded daily for last 3 months was 967.
-
What is the market cap of DRUG.CN currently?
-
The market value of DRUG.CN currently stands at $833.82M with its latest stock price at $107.43